The power of nanobot technology in cancer treatment

Bárbara B. Mendes; João Conde

doi:10.1016/j.matt.2024.06.031

The power of nanobot technology in cancer treatment

Bárbara B. Mendes, João Conde

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Abstract

Urease-powered nanobots significantly enhanced the efficacy of radionuclide therapy in bladder cancer treatment, showing superior tumor accumulation and penetration. This novel approach promises transformative advancements in managing non-muscle-invasive bladder cancer, as detailed in a recent study.

Original language	English
Pages (from-to)	2757-2760
Number of pages	4
Journal	Matter
Volume	7
Issue number	8
DOIs	https://doi.org/10.1016/j.matt.2024.06.031
Publication status	Published - 7 Aug 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.matt.2024.06.031

Cite this

@article{53d1814408ba483ca0ee2a2432de3148,

title = "The power of nanobot technology in cancer treatment",

abstract = "Urease-powered nanobots significantly enhanced the efficacy of radionuclide therapy in bladder cancer treatment, showing superior tumor accumulation and penetration. This novel approach promises transformative advancements in managing non-muscle-invasive bladder cancer, as detailed in a recent study.",

author = "Mendes, \{B{\'a}rbara B.\} and Jo{\~a}o Conde",

note = "Funding Information: J.C. and B.B.M. acknowledge the European Research Council (ERC Starting Grant Agreement 848325) and the Funda\textbackslash{}u00E7\textbackslash{}u00E3o para a Ci\textbackslash{}u00EAncia e Tecnologia (2022.07775. PTDC). J.C. is a co-founder and shareholder of TargTex S.A.-Targeted Therapeutics for Glioblastoma Multiforme. J.C. is a member of the Global Burden Disease (GBD) consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US), and the Scientific Advisory Board of Vector Bioscience, Cambridge. Funding Information: J.C. and B.B.M. acknowledge the European Research Council (ERC Starting Grant Agreement 848325 ) and the Funda\textbackslash{}u00E7\textbackslash{}u00E3o para a Ci\textbackslash{}u00EAncia e Tecnologia ( 2022.07775. PTDC ). Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = aug,

day = "7",

doi = "10.1016/j.matt.2024.06.031",

language = "English",

volume = "7",

pages = "2757--2760",

journal = "Matter",

issn = "2590-2393",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - The power of nanobot technology in cancer treatment

AU - Mendes, Bárbara B.

AU - Conde, João

N1 - Funding Information: J.C. and B.B.M. acknowledge the European Research Council (ERC Starting Grant Agreement 848325) and the Funda\u00E7\u00E3o para a Ci\u00EAncia e Tecnologia (2022.07775. PTDC). J.C. is a co-founder and shareholder of TargTex S.A.-Targeted Therapeutics for Glioblastoma Multiforme. J.C. is a member of the Global Burden Disease (GBD) consortium of the Institute for Health Metrics and Evaluation (IHME), University of Washington (US), and the Scientific Advisory Board of Vector Bioscience, Cambridge. Funding Information: J.C. and B.B.M. acknowledge the European Research Council (ERC Starting Grant Agreement 848325 ) and the Funda\u00E7\u00E3o para a Ci\u00EAncia e Tecnologia ( 2022.07775. PTDC ). Publisher Copyright: © 2024 Elsevier Inc.

PY - 2024/8/7

Y1 - 2024/8/7

N2 - Urease-powered nanobots significantly enhanced the efficacy of radionuclide therapy in bladder cancer treatment, showing superior tumor accumulation and penetration. This novel approach promises transformative advancements in managing non-muscle-invasive bladder cancer, as detailed in a recent study.

AB - Urease-powered nanobots significantly enhanced the efficacy of radionuclide therapy in bladder cancer treatment, showing superior tumor accumulation and penetration. This novel approach promises transformative advancements in managing non-muscle-invasive bladder cancer, as detailed in a recent study.

UR - https://www.scopus.com/pages/publications/85200354606

U2 - 10.1016/j.matt.2024.06.031

DO - 10.1016/j.matt.2024.06.031

M3 - Comment/debate

AN - SCOPUS:85200354606

SN - 2590-2393

VL - 7

SP - 2757

EP - 2760

JO - Matter

JF - Matter

IS - 8

ER -

The power of nanobot technology in cancer treatment

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this